medigraphic.com

2017, Number 1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2017; 18 (1)

Results and adverse reactions observed in patients treated with Heberprot-P® in the community setting

Hernández CCM, Jácome RR, Iturralde ML, Sánchez MME

Language: Spanish
References: 19
Page: 35-42
PDF size: 88.74 Kb.


ABSTRACT

Introduction: Diabetes mellitus is currently considered as an epidemic worldwide. With the rise of the prevalence of this disease, that of the diabetic foot with its different lesions increases too.
Objectives: To determine the results and the adverse reactions in patients treated with Heberprot-P® in the community setting.
Method: Prospective study of 17 patients with various diabetic foot lesions, who were seen in a health area from January 2012 to April 2013. They all received an outpatient treatment with Heberprot-P® (human recombinant epidermal growth factor) until complete granulation of lesions.
Results: In the group, 52.94 % of patients had grade 4 diabetic feet according to Wagner´s classification scale. All the treated patients showed satisfactory results and adverse reactions occurred six times in three patients.
Conclusions: Good results are achieved with the use of Heberprot-P® due to few adverse reactions and absence of amputation, mainly in diabetics with grade 4-foot ulcers in Wagner´s classification scale. This is a drug to be taken into consideration for curing diabetic foot ulcers since it can also be used in outpatient treatment.


REFERENCES

  1. Castro G. Guía clínica basada en evidencia pie diabético. Med Int Méx. 2009,25(6):481-526.

  2. Lozano F, Clará A, Alcalá D, Blanes JI, Doiz R, González del Castillo J, et al. Consensus document on treatment of infections in diabetic foot. Rev Esp Quimioter. 2011;24:233-62.

  3. Rincon Y, Gil V, Pacheco J, Benítez I, Sánchez M. Evaluación y tratamiento del pie diabético. Rev Venez Endocrinol Metab. 2012:10(3):176-87.

  4. Gómez Hoyos E, Esther Levy E, Díaz Pérez A, Cuesta Hernández M, Montañez Zorrilla C, Alfonso L. Pie diabético. Semin Fund Esp Reumatol. 2012;13(4):119-29.

  5. Acosta-Reyes MR, López A, Álvarez O, González AM, Acosta Altamirano G. Evaluación económica del uso de factor de crecimiento epidérmico recombinante humano (FCErh) en población mexicana con pie diabético en el Sector Salud. Rev Hosp Jua Mex. 2014;81(3):147-53.

  6. del Castillo Tirado R A, Fernández López JA, del Castillo Tirado FJ. Guía de práctica clínica en el pie diabético. Archivos de Med. 2014;10(2):1-7.

  7. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud. La Habana: MINSAP; 2015. Acceso: 3 Mar 2016. Disponible en: http://files.sld.cu/dne/files/2012/04/anuario-2015-e.pdf

  8. Mass Basulto G, Cabrera Rodríguez T, Torres Torres F, Vidal Cabrera G, Moya Ávila A, Alonso Abad J. Efectividad del Heberprot P en la úlcera de pie diabético en un área de salud. Rev Finlay. 2014;4(2). Acceso: 18 Jul 2016. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/255

  9. Rodríguez Gurri D. Caracterización de los pacientes con pie diabético tratados con Heberprot-P en el Hospital Militar de Holguín. Rev Cubana Angiol Cir Vasc. 2014;15(1):39-46. Acceso: 18 Jul 2016. Disponible en: http://scielo.sld.cu/pdf/ang/v15n1/ang06114.pdf

  10. Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63:3S-21S.

  11. Machado Cuetara RL, Bazan Machado MA, Izaguirre Bordelos M. Principales factores de riesgo asociados a las caídas en ancianos del área de salud Guanabo. MEDISAN. 2014;18(2):158-64. Acceso: 18 Jul 2016. Disponible en: http://bvs.sld.cu/revistas/san/vol18_2_14/san03214.htm

  12. Álvarez López A. Respuesta al tratamiento con Heberprot-P® según la severidad de la enfermedad arterial periférica. Rev Cubana Angiol Cir Vasc. 2016;17(2):130- 7. Acceso: 18 Jul 2016. Disponible en: http://bvs.sld.cu/revistas/ang/vol17_2_16/ang03216.htm

  13. Escobar Amarales Y, Torres Romo UR, Escalante Padrón O, Fernández Franch N, Ibarra Viena V, Miranda Rodríguez E. El Heberprot-P en el tratamiento de úlceras del pie diabético. AMC. 2014;18(39):297-308.

  14. Metzmacher I, Ruth P, Abel M. In vitro binding of matrix metalloproteinase-2 (MMP-2), MMP-9, and bacterial collagenase on collagenous wound dressings. Wound Repair Regen. 2007;15(4):549-55.

  15. Falabella AF, Valencia IC, Eaglstein WH, Schachner LA. Tissue-engineered skin (Apligraft) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol. 2000;136(10):1225-30.

  16. DiDomenico L, Landsman AR, Emch KJ, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cry preserved skin allograft or a bioengineered skin substitute. Wounds. 2011;23(7):184-9.

  17. Grosu-Bularda A, Manea C, Lazarescu L, Lascar I. The role of cartilage and bone Allografts in nasal reconstruction. Rom J Rhino. 2016;6(22):75-82.

  18. González de la Torre H, Mosquera Fernández A, Quintana Lorenzo ML, Perdomo Pérez E, del Pino Quintana Montes de Oca M. Clasificaciones de lesiones en pie diabético: Un problema no resuelto. Gerokomos. 2012;23(2):75-87.

  19. Montequín JI, Infante CE, Valenzuela SC, Franco PN, Savigne GW, Artaza SH, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-43.




2020     |     www.medigraphic.com